# Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM

Source: https://onco.cc/trials/nct05902169/  
OnCo record `nct05902169` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Carboplatin and Temozolomide in glioma & glioblastoma, run by CarThera, now recruiting.

## Summary

Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM is a phase 3 interventional study registered as NCT05902169 by CarThera, with 560 participants planned, started 2024-01-29 and due to reach its primary completion in 2028-01-28. Interventions recorded: SonoCloud-9 (SC9), Carboplatin, Lomustine and Temozolomide.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05902169
- Phase: 3
- Setting: A Randomized, Open-label, Multicentric, Two-arm Pivotal Trial of SonoCloud-9 Combined With Carboplatin (CBDCA) vs Standard of Care Lomustine (CCNU) or Temozolomide (TMZ) in Patients Undergoing Planned Resection for First Recurrence Glioblastoma.
- Sponsor: CarThera
- Enrolled: 560

## Sources

- ClinicalTrials.gov NCT05902169: https://clinicaltrials.gov/study/NCT05902169

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Temozolomide](https://onco.cc/drugs/temozolomide/)

---
JSON: https://onco.cc/api/v1/entities/nct05902169.json